AU714896B2 - Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure - Google Patents

Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure Download PDF

Info

Publication number
AU714896B2
AU714896B2 AU46540/96A AU4654096A AU714896B2 AU 714896 B2 AU714896 B2 AU 714896B2 AU 46540/96 A AU46540/96 A AU 46540/96A AU 4654096 A AU4654096 A AU 4654096A AU 714896 B2 AU714896 B2 AU 714896B2
Authority
AU
Australia
Prior art keywords
interaction agent
radiation
viral
viral vector
thymidine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU46540/96A
Other languages
English (en)
Other versions
AU4654096A (en
Inventor
Svend Freytag
Jae Ho Kim
San Hie Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Hospital
Original Assignee
Henry Ford Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Hospital filed Critical Henry Ford Hospital
Publication of AU4654096A publication Critical patent/AU4654096A/en
Application granted granted Critical
Publication of AU714896B2 publication Critical patent/AU714896B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
AU46540/96A 1995-01-04 1996-01-04 Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure Ceased AU714896B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36860295A 1995-01-04 1995-01-04
US08/368602 1995-01-04
PCT/US1996/000148 WO1996020733A1 (en) 1995-01-04 1996-01-04 Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure

Publications (2)

Publication Number Publication Date
AU4654096A AU4654096A (en) 1996-07-24
AU714896B2 true AU714896B2 (en) 2000-01-13

Family

ID=23451926

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46540/96A Ceased AU714896B2 (en) 1995-01-04 1996-01-04 Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure

Country Status (5)

Country Link
EP (1) EP0814845A4 (de)
JP (1) JPH10511853A (de)
AU (1) AU714896B2 (de)
CA (1) CA2207974A1 (de)
WO (1) WO1996020733A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9924981D0 (en) 1999-10-21 1999-12-22 Univ Manchester Gene therapy
GB2397063A (en) * 1999-10-21 2004-07-14 Cedars Sinai Medical Center A medicament comprising a cytotoxic pro drug activated by HSV TK
EP1786474B1 (de) 2004-08-12 2011-06-01 Cedars-Sinai Medical Center Kombinierte gentherapie zur behandlung makroskopischer glioma
US8883493B2 (en) 2007-01-30 2014-11-11 Cedars-Sinai Medical Center Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026743A1 (en) * 1995-03-01 1996-09-06 Human Gene Therapy Research Institute Radiation enhanced gene therapy for treatment of tumors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RES. 53(1993) PP 83-88, RAM ET AL *
INT. J. RAD. ONC. BIOL. PHYS, VOL 12, P 1537-1540 (1986) *

Also Published As

Publication number Publication date
EP0814845A1 (de) 1998-01-07
WO1996020733A1 (en) 1996-07-11
CA2207974A1 (en) 1996-07-11
JPH10511853A (ja) 1998-11-17
AU4654096A (en) 1996-07-24
EP0814845A4 (de) 2001-08-08

Similar Documents

Publication Publication Date Title
Solly et al. Replicative retroviral vectors for cancer gene therapy
US5837510A (en) Methods and polynucleotide constructs for treating host cells for infection or hyperproliferative disorders
US6110458A (en) Cancer therapy utilizing ex vivo gene transduction
Rainov et al. Clinical trials with retrovirus mediated gene therapy–what have we learned?
JPH07501690A (ja) 霊長類の骨髄細胞を遺伝的に修飾する方法、および該方法のために有用な、組換えレトロウイルスベクターを産生する細胞
JPH08506722A (ja) 腫瘍を治療するためのレトロウイルスベクターおよびそれらを含む細胞系統
JPH09504518A (ja) 負の選択マーカーおよびサイトカインをコード化する遺伝子を用いる腫瘍細胞の遺伝子転換による腫瘍の治療
AU714896B2 (en) Treatment of tumors by transduction with negative selective markers, application of interaction agents and subsequent radiation exposure
CA2169557A1 (en) Treatment of human tumors by genetic transformation of human tumor cells
EP0880594B1 (de) Retroviraler vektor und dessen verwendung in gentherapie
Hayashi et al. An experimental application of gene therapy for human retinoblastoma.
US6677155B1 (en) Triple hybrid amplicon vector systems to generate retroviral packaging lines
Maza et al. Establishing chemoresistance in hematopoietic progenitor cells
Schmidt-Wolf et al. Human cancer and gene therapy
Mineishi et al. Co-expression of the herpes simplex virus thymidine kinase gene potentiates methotrexate resistance conferred by transfer of a mutated dihydrofolate reductase gene
US6130089A (en) Materials and methods for gene transfer
WO2001079502A2 (en) Vectors for gene therapy
Schuening et al. Retroviral transfer of genes into canine hematopoietic progenitor cells
Howard et al. Ablation of Tumor Cells In Vivo by Direct Injection of HSV‐Thymidine Kinase Retroviral Vector and Ganciclovir Therapy
O’Malley Jr Suicide gene therapy
Kelley et al. The Jeremiah Metzger lecture. Current status of human gene therapy
Mineishi Augmentation of methotrexate resistance with coexpression of metabolically related genes
Tzeng et al. Genetic Modulation of inducible nitric oxide synthase expression
Bertino et al. Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells
Walling Gene Therapy for Osteosarcoma:" In Vitro" Characterization of Five Tumor Cell Lines and Development of Treatment Models" In Vivo"

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired